Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats

被引:66
|
作者
Sancho, V
Trigo, MV
González, N
Valverde, I
Malaisse, WJ
Villanueva-Peñacarrillo, ML
机构
[1] Fdn Jimenez Diaz, Dept Metab Nutr & Hormones, E-28040 Madrid, Spain
[2] Free Univ Brussels, Lab Expt Hormonol, Brussels, Belgium
关键词
D O I
10.1677/jme.1.01747
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several kinases have been implicated in the metabolic response of human and rat myocytes to glucagon-like peptide-1 (GLP-1), exendin-4 (Ex-4) and exendin-9 (Ex-9). We have investigated, in isolated rat adipocytes, the changes caused by GLP-1, Ex-4 and Ex-9 compared with those provoked by insulin or glucagon, upon the activity of phosphatidylinositol-3-kinase (PI3K), protein kinase B (PKB), p42/44 MAP kinases (MAPKs) and p70s6 kinase (p70s6k), and the participation of these kinases and protein kinase C (PKC) in their action upon 2-deoxy-(D)-glucose uptake, lipolysis and lipogenesis. The study was conducted in normal rats, and extended to a streptozotocin-induced type-2 diabetic model (STZ-rats). The participation of distinct kinases was estimated by using potential kinase inhibitors, including wortmannin, PD98059, rapamycin, H-7 and RO31-8220. In normal rat adipocytes, GLP-1 and both exendins share with insulin an increasing action upon the activity of all kinases studied (except PKB), PI3K, p44 and p42 MAPKs and possibly PKC, all being required for their stimulating effect upon glucose uptake. Ex-4 and Ex-9, like GLP-1 and insulin, have lipogenic action, while only Ex-4 shares with GLP-1 its lipolytic effect which is antagonized by Ex-9. MAP kinases and PKC seem to have an essential role in the GLP-11 and Ex-4 lipolytic action, as does PI3K in that of Ex-4. An increase in PI3K and MAPKs activity for the lipogenic effect of Ex-4, Ex-9 and GLP-1 are required, and in the case of Ex-4 and Ex-9, a stimulation of p70s6k activity is also needed. In cells from STZ-rats the magnitude of the above parameters was, in general, comparable to that in normal animals, with some exceptions: basal PI3K activity and lipogenesis were higher, GLP-1, Ex-4 and Ex-9 failed to modify basal lipogenesis but increased PKB activity, insulin failed to affect the activity of MAPKs and the insulin-induced glucose uptake was impaired. The impaired insulin effects upon some of the variables in the STZ-rat, distinct from those of GLP-1 and exendins, adds knowledge to the mechanism of the beneficial action of GLP-1 and Ex-4 in diabetic states.
引用
收藏
页码:27 / 38
页数:12
相关论文
共 50 条
  • [1] Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
    Lutz, Thomas A.
    Osto, Elena
    CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) : 257 - 263
  • [2] Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
    El Bekay, Rajaa
    Coin-Araguez, Leticia
    Fernandez-Garcia, Diego
    Oliva-Olivera, Wilfredo
    Bernal-Lopez, Rosa
    Clemente-Postigo, Mercedes
    Delgado-Lista, Javier
    Diaz-Ruiz, Alberto
    Guzman-Ruiz, Rocio
    Vazquez-Martinez, Rafael
    Lhamyani, Said
    Mar Roca-Rodriguez, Maria
    Fernandez Veledo, Sonia
    Vendrell, Joan
    Malagon, Maria M.
    Jose Tinahones, Francisco
    BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (11) : 1820 - 1834
  • [3] On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects
    Holst, JJ
    ToftNielsen, MB
    Orskov, C
    Nauck, M
    Willms, B
    VIP, PACAP, AND RELATED PEPTIDES, 2ND INTERNATIONAL SYMPOSIUM, 1996, 805 : 729 - 736
  • [4] Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes
    Yanai, Hidekatsu
    Hamasaki, Hidetaka
    Adachi, Hiroki
    Moriyama, Sumie
    Hirowatari, Yuji
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 1 (03) : 149 - 151
  • [5] Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
    Bu, Tong
    Sun, Ziyan
    Pan, Yi
    Deng, Xia
    Yuan, Guoyue
    DIABETES & METABOLISM JOURNAL, 2024, 48 (03) : 354 - 372
  • [6] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [7] Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
    Jan Hansen
    Birgitte Brock
    Hans Erik Bøtker
    Albert Gjedde
    Jørgen Rungby
    Michael Gejl
    Reviews in Endocrine and Metabolic Disorders, 2014, 15 : 219 - 231
  • [8] Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
    Hansen, Jan
    Brock, Birgitte
    Botker, Hans Erik
    Gjedde, Albert
    Rungby, Jorgen
    Gejl, Michael
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2014, 15 (03): : 219 - 231
  • [9] EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 ON THE PANCREAS OF OLETF RATS
    Tian, Xiaojuan
    Sun, Xuedong
    Wang, Yanhui
    Zhao, PengCheng
    ACTA MEDICA MEDITERRANEA, 2022, 38 (06): : 3677 - 3682
  • [10] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37